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The aim of this study was to determine the efficacy of palliative oxygen for relief of dyspnoea in cancer patients. MEDLINE and
EMBASE were searched for randomised controlled trials, comparing oxygen and medical air in cancer patients not qualifying for home
oxygen therapy. Abstracts were reviewed and studies were selected using Cochrane methodology. The included studies provided
oxygen at rest or during a 6-min walk. The primary outcome was dyspnoea. Standardised mean differences (SMDs) were used to
combine scores. Five studies were identified; one was excluded from meta-analysis due to data presentation. Individual patient data
were obtained from the authors of the three of the four remaining studies (one each from England, Australia, and the United States).
A total of 134 patients were included in the meta-analysis. Oxygen failed to improve dyspnoea in mildly- or non-hypoxaemic cancer
patients (SMD¼ 0.09, 95% confidence interval  0.22 to 0.04; P¼0.16). Results were stable to a sensitivity analysis, excluding
studies requiring the use of imputed quantities. In this small meta-analysis, oxygen did not provide symptomatic benefit for cancer
patients with refractory dyspnoea, who would not normally qualify for home oxygen therapy. Further study of the use of oxygen in
this population is warranted given its widespread use.
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Dyspnoea is common, affecting 50–70% of patients with advanced
cancer (Reuben and Mor, 1986; Ripamonti, 1999; Bruera et al,
2000). Defined by the American Thoracic Society as ‘a subjective
experience of breathing discomfort that consists of qualitatively
distinct sensations that vary in intensity’, dyspnoea is a
very personal experience (ATS, 1999). Descriptions vary
widely; examples include ‘short of breath’, ‘hard to move air’,
‘chest tightness’, ‘choking’, ‘panting’, and ‘gasping’ (Brown et al,
1986; Simon et al, 1989; Roberts et al, 1993; Harver et al, 2000).
The experience of dyspnoea can be affected by many conditions,
including the cancer itself, coexisting diseases, and cancer cachexia
(Reuben and Mor, 1986; Ripamonti, 1999; Bruera et al, 2000).
Dyspnoea in cancer survivors has also been correlated with
psychological status, including both anxiety and depression
(Bruera et al, 2000; Tanaka et al, 2002a), and over 20% of
cancer patients report interference with psychological functioning
(Tanaka et al, 2002b).
The sensation cannot always be explained by organic
causes (Ahmedzai, 1998; Bruera and Ripamonti, 1998) and is
influenced by pathways and interactions at multiple levels of the
nervous system (Bruera et al, 2000). Dyspnoea appears to be a
subjective sensation that is not a direct representation of the
intensity of the stimulus in the nervous system but rather the
result of an interaction among production, perception, and
expression (Ripamonti and Bruera, 1997; Bruera and Ripamonti,
1998).
Management of dyspnoea presents a challenge because there is
no roadmap to guide therapy. The typical recommendation is to
relieve dyspnoea by treating the underlying cause, but this is often
not successful or simply not possible in people with advanced
cancer. In these cases, dyspnoea is termed ‘refractory’ (Abernethy
et al, 2003) and the focus is on symptom control in an effort to
decrease the sensation of dyspnoea. Clinicians choose from a
number of palliative interventions, including opioids, psychotropic
agents, and nebulised furosemide.
There are data on the role of oxygen in changing survival in
hypoxaemic patients (PaO2o55mmHg) with COPD (chronic
obstructive pulmonary disease) (NOTTG, 1980; MRCWP, 1981).
Data regarding the role of oxygen in relieving the sensation of
breathlessness are inconclusive. Evidence for the use of oxygen to
relieve the sensation of dyspnoea, the so-called ‘palliative oxygen’,
in patients with malignancy, is also lacking. Despite this, use of
palliative oxygen to relieve breathlessness toward the end of life is
supported by consensus guidelines (Kvale et al, 2003; Storey and
Knight, 2003; Booth et al, 2004) and is a common practice. For
example, a recent survey of 648 palliative-care specialists and
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srespiratory physicians in Australia and New Zealand demonstrated
that palliative oxygen is commonly prescribed with 58% of 214
respondents reporting a belief that palliative oxygen is beneficial
and 65% reporting that the most common reason for
prescribing oxygen was refractory dyspnoea (Abernethy et al,
2005). Canadian physicians report similar practices (Stringer
et al, 2004).
The discrepancy between clinical practice and available evidence
has several implications. First, patients may be prescribed
ineffective treatments. Additionally, oxygen is not a benign
intervention. Quality of life may be limited as a result of functional
restriction from tubing, tanks, or concentrators; there may be
psychological distress in being reliant on a machine (Currow et al,
2007); nasal cannulae might irritate the nose and increase the risk
of epistaxis. Home oxygen therapy is also expensive. If patients do
not meet funding criteria for home oxygen, they must pay out-of-
pocket or receive the intervention on compassionate-use grounds.
Funding for home oxygen therapy is a common reason for referral
to hospice care. In Canada, about 40% of patients receiving home
oxygen do not meet funding guidelines and receive this inter-
vention on a compassionate-use basis (Guyatt et al, 2000).
In an attempt to improve the understanding of the optimal use
of palliative oxygen in patients with malignancy, we conducted a
systematic review and meta-analysis aimed at answering the
following question: ‘in mildly hypoxaemic or non-hypoxaemic
cancer patients with breathlessness, does oxygen therapy improve
symptoms?’
METHODS
Definitions and outcomes
Oxygen administered by a non-invasive method was defined as
oxygen delivered by nasal cannula, mouthpiece, or face mask.
Studies that evaluated the effects of oxygen on dyspnoea, either at
rest or on exertion, as measured by patient self-report, were
sought. Secondary outcomes of interest included quality of life,
patient preference, and functional status.
Search strategy
A general search aimed at identifying articles evaluating the use of
oxygen in the context of breathlessness was identified by exploding
the MeSH terms dyspnoea, oxygen, and oxygen inhalation therapy
and combining them. The text words oxygen, dyspnoea, and
breathlessness were also included. The article set generated by this
search was then combined with a standard search for randomised
controlled trials (Dickersin et al, 1994). The strategies were
executed in MEDLINE and EMBASE (from 1966 to December
2006), and were limited to articles involving adult human beings
and published in English. Reference lists of included studies and
relevant systematic reviews were hand searched.
Literature screening
Abstracts and full-text versions of articles identified in MEDLINE,
EMBASE, and other searches were screened by two investigators
(HU and AA) against the following eight exclusion criteria:
  Study design was not a randomised controlled trial;
  Study subjects were not adults with malignancy;
  Study subjects had a mean PaO2o55mmHg or more than 50%
of subjects had oxygen saturation o88% by pulse oximetry;
  Study subjects were already receiving home oxygen therapy;
  Study intervention was not oxygen vs placebo;
  Method of oxygen delivery was something other than nasal
cannula, mouthpiece, or mask;
  No dyspnoea outcomes were reported; and,
  ‘Other’ reason (e.g., study articles were not editorial or review
article).
All abstracts were reviewed by two oncologists (HU and AA) and
any article selected by either reviewer was included for full-text
review. All full-text articles were reviewed by both oncologists (HU
and AA), and the full-text articles meeting all inclusion criteria
were selected for full abstraction. Differences in judgment were
resolved by consensus conference.
Data abstraction
For each article meeting the inclusion criteria, basic study
parameters were abstracted into evidence tables summarising the
following: study design, primary focus, inclusion/exclusion criteria,
interventions and how administered, subjects, outcomes, results,
and quality assessment. Abstractions were performed by one
investigator (HU) and were over-read by a second investigator
(AA) to ensure accuracy.
Quality assessment
Studies were assessed for both internal and external validity.
Internal validity criteria included randomisation, blinding, and
description of withdrawals/dropouts, and each study was assigned
a Jadad score (Jadad et al, 1996). External validity criteria included
subject description, detailed intervention description, and ade-
quately reported dyspnoea outcomes.
Data analysis
Dyspnoea ratings measured by modified Borg, 0–10 numerical
rating scale (NRS), 100mm visual analog scale (VAS), or 300mm
VAS were converted into standardised mean differences (SMDs).
Results of both periods of crossover trials were used. Crossover
trials should be included in meta-analyses using results from
paired analyses. However, these data are often not available.
In these cases, standard errors were estimated using methods
described by Follmann et al (1992). Correlations between
repeated outcomes were estimated from P-values when available
and, when unavailable, the lowest estimate from other studies was
used.
Statistical analyses, except meta-analyses, were conducted using
SAS E-Guide version 3 for Windows (SAS Institute, Cary, NC,
USA). Meta-analyses were conducted for those studies where
means and variances for dyspnoea measurements could be
estimated from published reports. Authors were contacted for
additional data if published information was not sufficient. For
meta-analyses, effect sizes were calculated using Cochrane soft-
ware, RevMan 4.2.8., and are reported as SMD with 95%
confidence intervals (CIs). Two-sided P-values are reported and
statistical significance was assumed if Po0.05 (Supplementary
Information).
RESULTS
Article review
The flow of articles reviewed is presented in Figure 1. This study
on cancer was conducted in conjunction with a second review that
focused on COPD and other aetiologies of breathlessness. Studies
that did not include cancer patients were excluded from this
analysis. The five abstracted articles represent data from five
different studies (Table 1; Bruera et al, 1993, 2003; Booth et al,
1996; Ahmedzai et al, 2004; Philip et al, 2006).
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sStudy characteristics
Design characteristics All five studies included in this analysis
were blinded, randomised, and controlled crossover trials. In this
type of trial, participants are assigned to study arms consisting of
two or more treatments given consecutively and in random order
(Sibbald and Roberts, 1998). Each subject acts as his/her own
control, so that the response to treatment A can be compared with
that of treatment B without concern for issues involving patient
variation, if the duration of therapy in each arm means that the
other factors affecting the symptom are likely to remain stable for
the entire study. Crossover trials are commonly used in palliative-
care research given the ability to directly compare two treatments
in the same patient and the ability to answer a clinical question
with fewer subjects than is required in a traditional parallel group
trial. As is typical for palliative-care studies, sample sizes in the
five studies included were small with a median of 33 participants
per study and a mean of 29.6 (s.d. 16.5). None of the studies
included had evidence of calculations required to claim adequate
power to answer the questions.
Patient characteristics The five included studies represented 148
participants, all of them adults. Median participant age was 65 and
39% were females; no information was available on race or
ethnicity. Participants had several different types of malignancy,
with lung cancer (65%) or unspecified cancer with metastasis to
the lung (15%) being most common. The profile of other
malignancies was as follows: breast (5%), colon (3%), and others,
including lymphoma, melanoma, sarcoma, carcinoid, skin, bladder,
and head and neck (7%). Baseline percent oxygen saturation that
was provided by four out of five studies are as follows: median 93%
(Philip et al, 2006), median 94% (Ahmedzai et al, 2004), median
98% (Bruera et al, 2003), and range 80–99% (Booth et al, 1996).
Baseline dyspnoea at rest that was provided in three out of five
studies are as follows: 0mm by modified Borg (Ahmedzai et al,
2004), 5mm by NRS (Bruera et al, 2003), and 59mm by 100mm
VAS (Booth et al, 1996).
Intervention characteristics Four studies (Bruera et al, 1993,
2003; Booth et al, 1996; Philip et al, 2006) were focused on
evaluating oxygen vs medical air for relief of dyspnoea, whereas the
fourth evaluated the use of Heliox28, a novel agent containing 72%
helium and 28% oxygen vs oxygen and medical air (Ahmedzai
et al, 2004). Oxygen was delivered by nasal canula in three studies
(Booth et al, 1996; Bruera et al, 2003; Philip et al, 2006) and by
mask in two (Bruera et al, 1993; Ahmedzai et al, 2004); doses of
oxygen ranged from 3 to 5lmin
 1. Oxygen was administered at
rest in three studies (Bruera et al, 1993; Booth et al, 1996; Philip
et al, 2006) and during a 6MWT (6-min walk test) in two studies
(Bruera et al, 2003; Ahmedzai et al, 2004).
Treatment efficacy
Estimation of treatment efficacy Overall, the quality of reporting
was poor with four out of five studies having a Jadad score of 2,
indicating inadequate discussion of methods of both randomisa-
tion and blinding (Jadad et al, 1996). Only one out of five studies
provided sufficient information to calculate SMD and variances for
Table 1 Characteristics of included studies exploring the role of oxygen therapy in people with refractory dyspnoea who do not qualify for long-term
oxygen therapy
Reference n Population
O2 saturation
o90% included? Intervention
Outcome
measure Results Quality
a
(Philip et al, 2006) 51 Cancer of any type,
dyspnoea
Yes 17 (33%) CA vs O2,4lm i n
 1
at rest
100mm VAS No significant
difference in dyspnoea
with O2 vs CA
2
(Ahmedzai et al, 1998,
2004)
12 Lung cancer, dyspnoea
on exertion
No CA vs O2,8–10lmin
 1
during 6MWT
Modified Borg and
100mm VAS
No significant
difference in dyspnoea
with O2 vs CA
2
(Bruera et al, 2003) 33 Advanced cancer of
any type, dyspnoea at
rest or on mild exertion
No CA vs O2,5lm i n
 1
during 6MWT
NRS No significant
difference in dyspnoea
with O2 vs CA
5
(Booth et al, 1996, 2004) 38 Advanced cancer of
any type, dyspnoea at
rest
Yes 6 (16%) CA vs O2,4lm i n
 1
at rest
Modified Borg and
100mm VAS
No significant
difference in dyspnoea
with O2 vs CA
2
(Bruera et al, 1993) 14 Advanced cancer of
any type, dyspnoea,
oxygen saturation
o 90%
Yes 14 (100%) CA vs O2 5lmin
 1
at rest
NRS Significant
improvement in
dyspnoea with O2 vs
CA
2
Abbreviations: CA¼compressed air; O2¼oxygen; 6MWT¼6-min walk test; VAS¼visual analog scale; NRS¼numerical rating scale.
aQuality as assessed by Jadad score (Jadad
et al, 1996).
Total citations reviewed 
204 
Total full-text articles reviewed 
54 (26%) 
150 excluded 
at the abstract 
review stage 
25 excluded at 
the full-text 
review stage 
Total articles abstracted 
into evidence tables 
Malignancy=5 (2.5%) 
COPD=21 (10%) 
Other=3 (1.5%) Total 
excluded
152 
Figure 1 Flowchart of articles reviewed for the systematic analysis of the
benefit of palliative oxygen for the relief of dyspnoea in people with cancer
who do not qualify for long-term domiciliary oxygen therapy.
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sdyspnoea measurements. As a result, all the authors were
contacted to request individual patient data. All the authors
responded; individual patient data were available for three
studies (Booth et al, 1996; Bruera et al, 2003; Philip et al, 2006)
and were unavailable for the other two (Bruera et al, 1993;
Ahmedzai et al, 2004). Using correlations calculated from
available data, it was possible to derive s.e. for a fourth study
(Ahmedzai et al, 2004). The remaining study (Bruera et al, 1993)
was excluded from meta-analysis, leaving 134 patients included.
Oxygen failed to improve dyspnoea in mildly- or non-hypoxaemic
cancer patients (SMD¼ 0.09, 95% CI  0.22 to 0.04; P¼0.16)
(Figure 2). This finding is consistent with a global assessment
reflecting that four out of five individual studies were negative.
Sensitivity analysis excluding the study requiring the use of
imputed quantities was performed; results were stable in this
analysis (Figure 3).
Other outcomes Two out of five included studies also reported
the impact of oxygen on results of the distance walked during the
6MWT (Bruera et al, 2003; Ahmedzai et al, 2004). One study
reported a statistically significant increase in the distance with the
use of oxygen (174.6m (s.d. 11.2)) vs medical air (128.8m (s.d.
10.3)) (Po0.01) (Ahmedzai et al, 2004). However, a second study
reported no difference in distance with oxygen (331.6m (s.d. 54.9))
and with medical air (330.7 (s.d. 57.6)) (Bruera et al, 2003). Four
out of five studies reported results of still-blinded patient
preference for oxygen vs medical air. Two out of four studies
reported a statistically significant still-blinded patient preference
for oxygen vs air, whereas the other two found no such difference
(Table 2).
DISCUSSION
Oxygen was not effective at reducing the sensation of dyspnoea in
cancer patients who would not otherwise qualify for home
oxygen therapy, with an SMD¼ 0.09 (95% CI:  0.22 to 0.04;
P¼0.16) translating into a 0.19-cm reduction in dyspnoea on a
10cm VAS or a 0.22-point reduction in dyspnoea on a 0–10 NRS.
When evaluating interventions for dyspnoea, most clinicians
would consider a change of 10cm on a 10cm VAS or a 1-point
reduction on a 0–10 NRS to be clinically significant. So, the
observed reduction does not represent a clinically significant
change.
Two out of five studies evaluated the impact of oxygen on
exercise tolerance by evaluating patients during a 6MWT
conducted either with oxygen or medical air. The results were
conflicting with one study finding a clinically and statistically
significant improvement in distance walked with oxygen as
opposed to air and the other failing to do so. Why might this be
the case? It is not immediately clear because the two populations
were very similar. In the study by Bruera et al (2003), median age
was 64 years, 64% were male, 94% had primary lung cancer,
median baseline oxygen saturation was 98%, and median usual
dyspnoea on activity (as measured by 0–10 NRS) was 5. In the
study by Ahmedzai et al (2004), median age was 72.5 years, 58%
Review: Palliative oxygen therapy for dyspnea in patients with malignancy
01 breathlessness
01 breathlessness
SMD (s.e.) SMD (fixed) (95% Cl) SMD (fixed) (95% Cl) Quality Weight (% )
Comparison:
Outcome:
Study 
or subcategory
Bruera –0.1600 (0.2100) –0.16 [–0.57, 0.25] D
D
D
D
–0.12 [–0.28, 0.04]
–0.65 [–1.45, 0.15]
–0.09 [–0.18, 0.36]
–0.09 [–0.22, 0.04]
–0.1200 (0.0800)
9.61
66.24
2.52
21.63
100.00
–0.6500 (0.4100)
–0.0900 (0.1400)
–4 –2
Favours oxygen Favours air
024
Booth
Ahmedzai
Philip
Total (95% Cl)
Test for heterogeneity: 2=3.77, df=3 (P=0.29), l
2=20.4%
Test for overall effect: Z=1.41 (P=0.16)
Figure 2 Estimation of efficacy of oxygen in the treatment of dyspnoea in cancer patients who do not qualify for long-term domiciliary oxygen therapy.
Review: Palliative oxygen therapy for dyspnea in patients with malignancy
01 breathlessness
02 breathlessness no imputed quantities
Comparison:
Outcome:
SMD (s.e.) SMD (fixed) (95% Cl) SMD (fixed) (95% Cl) Quality Weight (% )
Study 
or subcategory
Bruera
Booth
Philip
Total (95% Cl)
Test for heterogeneity: 2=1.87, df=2 (P=0.39), l
2=0%
Test for overall effect: Z=1.17 (P=0.24)
–0.1600 (0.2100)
–0.1200 (0.0800)
–0.0900 (0.1400)
–0.16 [–0.57, 0.25]
–0.12 [–0.28, 0.04]
–0.09 [–0.18, 0.36]
9.86
67.95
22.19
–0.08 [–0.21, 0.05] 100.00
D
D
D
Favours treatment
–1 –0.5 0 0.5 1
Favours control
Figure 3 Sensitivity analysis of blinded, randomised controlled trials exploring the symptomatic benefit of oxygen therapy in reducing refractory dyspnoea
in a palliative population which does not qualify for domiciliary oxygen – no studies requiring use of imputed quantities.
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swere male, 100% had primary lung cancer, median baseline oxygen
saturation was 94%, and median dyspnoea on exertion (as
measured by modified Borg) was 3. The similarities between the
two samples suggest that the conflicting results are likely due to
chance and that further study is warranted.
Patient preference was also discussed in two out of four studies.
This is known to be important as the COPD literature has
demonstrated that even patients shown to get benefited from
oxygen do not always wish to receive it (Eaton et al, 2002; Currow
et al, 2007). It is also a critical issue given the subjective nature of
dyspnoea and the fact that patients often have difficulty in
describing the sensation (ATS, 1999). Unfortunately, the data on
patient preference are not definitive, with only two out of four
studies demonstrating statistically significant patient preference
for oxygen. Again, the reason for this lack of agreement is not
clear, but it may be a result of small sample size and/or relative
heterogeneity in the study population. Interestingly, one of the
studies reporting a significant patient preference for oxygen
(Bruera et al, 2003) failed to find a statistically significant
improvement in dyspnoea as measured by the 0–10 NRS. This
may reflect the subjective nature of dyspnoea as well as the
difficulties in measuring the sensation, particularly in cancer
patients.
Our systematic review does have several strengths. First, the
search was conducted in both MEDLINE and EMBASE, allowing
incorporation of a broad range of publications and increasing our
ability to identify articles addressing this specific question. Second,
we contacted the authors of the included studies for additional
data. All responded and individual patient data were subsequently
available for an additional three studies, significantly strengthen-
ing our meta-analysis. Third, we followed Cochrane methodology
for study review, data abstraction, and data analysis.
In addition to the inherent issues associated with the current
body of literature evaluating the optimal use of oxygen in
dyspnoeic cancer patients who did not qualify for the home
oxygen therapy, there are several limitations specific to our review.
First, patients were included in each of the studies based on oxygen
saturation as measured by pulse oximetry, a reasonably accurate
way of evaluating oxygenation but one that is affected by a number
of physiologic variables, including haemoglobin level, 2,3-diphos-
phoglycerate levels, arterial blood flow, temperature of the digit
where the oximeter is located, skin pigmentation, and motion
artifact (Jensen et al, 1998). Although direct measurement of
arterial oxygen saturation by arterial blood gas analysis would be
preferable, the use of pulse oximetry is not surprising given that
these studies were performed in a palliative-care population where
invasive testing is typically minimised. Second, the patient
population represents a mixture of individuals with oxygen
saturations both above and below 90% by pulse oximetry. While
we set out to exclude studies evaluating patients who were clearly
hypoxaemic (PaO2o55mmHg), it became clear that this would not
be possible due to the lack of arterial blood gas data. We attempted
to decrease the impact on our analysis by excluding those studies
where more than 50% of participants had a baseline oxygen
saturation of o90% (roughly equivalent to a PaO2 of 60mmHg
using the oxyhaemoglobin dissociation curve) from meta-analysis;
no studies meeting this criterion were identified. As a result, we
may have included individuals with PaO2o55mmHg and/or
excluded individuals with PaO2¼55–59mmHg. Both scenarios
could certainly impact our analysis although there are no available
data to suggest the direction in which that impact would be seen.
Third, the sample size was small (n¼148) and 65% of patients
carried a diagnosis of lung cancer. This limits the generalizability
of these results to a population of patients with a wider range of
malignancies given the number of factors that contribute to
dyspnoea in this population.
In summary, available data do not provide support for the use of
palliative oxygen for relief of the sensation of refractory dyspnoea
in cancer patients. However, limitations in the data make it
difficult to come to firm conclusions on such an important issue as
evidenced by the fact that clinicians across the globe continue to
prescribe oxygen for refractory dyspnoea (Abernethy et al, 2005).
The data on patient preference, obtained when patients were still-
blinded to the intervention, suggest that there is a population of
patients who experience less dyspnoea while receiving oxygen as
compared with medical air. Further research is required to
appropriately identify these subgroups of people. Until such data
are available, decisions regarding the use of palliative oxygen can
be made on an individual basis after an ‘n of 1’ assessment as
described by Bruera et al (1992).
Table 2 Blinded patient preference in the four randomised controlled studies that were assessing the role of oxygen in relieving refractory dyspnoea in
people who currently do not qualify for long-term domiciliary oxygen therapy
Reference n Population Patient preference
(Philip et al, 2006) 51 Cancer of any type, dyspnoea Preference for oxygen¼21 (41%)
Preference for air¼15 (29%)
No preference¼15 (29%)
(Ahmedzai et al, 1998, 2004) 12 Lung cancer, dyspnoea on exertion Not reported
(Bruera et al, 2003) 33 Advanced cancer of any type, dyspnoea at rest or
on mild exertion
Preference for oxygen¼19 (58%)
a
Preference for air¼11 (33%)
a
No preference¼3 (9%)
(Booth et al, 1996, 2004) 38 Advanced cancer of any type, dyspnoea at rest Preference for oxygen¼15 (54%)
b
Preference for air¼11 (39%)
b
Worse with oxygen¼2 (7%)
b
Worse with air¼3 (11%)
b
(Bruera et al, 1993) 14 Advanced cancer of any type, dyspnoea, oxygen
saturation o90%
Preference for oxygen¼12 (86%)
c
Preference for air¼1 (7%)
c
No preference¼1 (7%)
c
aPo0.05 for comparison.
bBased only on those who made some comment (n¼28).
cPo0.001 for comparison.
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